TLDR

Hyperbaric oxygen therapy (HBOT) is a clinically grounded, adjunct treatment that supports cancer patients by correcting the six dysfunctional terrain states cancer exploits to grow and resist treatment. At OxygenWell, we combine physician-directed HBOT protocols with photobiomodulation and functional medicine to help patients reduce treatment toxicity, rebuild cellular resilience, and support long-term survivorship — all within a physician-owned, FDA-cleared facility in Sherman Oaks and Calabasas.

Table of Contents

• What Is Hyperbaric Oxygen Therapy for Cancer Patients?
• The Metabolic Terrain Model: Why Cancer Thrives
• How HBOT Restores the Terrain
• Does HBOT Promote Cancer Growth? What the Evidence Says
• The 4-Phase HBOT Dose Model for Cancer Support
• HBOT Timing Around Chemotherapy
• Chemotherapy Drug Interactions and Contraindications
• HBOT and Radiation Therapy
• Combined HBOT and Photobiomodulation Protocol
• Long-Term Survivorship Support
• Why OxygenWell for Integrative Oncology Support
• About the Author

What Is Hyperbaric Oxygen Therapy for Cancer Patients?

Hyperbaric oxygen therapy (HBOT) involves breathing 100% medical-grade oxygen inside a pressurized chamber, typically at 1.3 to 2.4 atmospheres absolute (ATA). Under elevated pressure, oxygen dissolves directly into plasma — bypassing red blood cells entirely — and reaches tissues, bones, and organs that are normally oxygen-starved due to compromised circulation or disease-related damage.

For cancer patients, HBOT is not a standalone cancer treatment and should never be framed as a cure. Its clinical value is as a precision adjunct therapy: a tool that targets the underlying physiological dysfunction cancer creates and exploits. When integrated properly with conventional oncology care, HBOT can reduce treatment toxicity, accelerate tissue repair, improve quality of life, and help the body rebuild the terrain that cancer has systematically degraded.

OxygenWell's cancer support program is built on one foundational principle: cancer thrives in a broken terrain. Restore the terrain, and you change what is possible.

The Metabolic Terrain Model: Why Cancer Thrives in Six Dysfunctional States

Modern integrative oncology increasingly recognizes that cancer does not simply appear — it establishes itself within a physiological environment that has become permissive to its growth. This is the terrain model: the idea that the cellular and systemic environment either resists or enables cancer progression.

OxygenWell's approach to cancer support targets the six core terrain dysfunctions that research consistently links to tumor survival, treatment resistance, and poor outcomes:

1. Hypoxia

Tumors actively create hypoxic (low-oxygen) microenvironments. Hypoxia drives angiogenesis, promotes metastasis, and dramatically reduces the effectiveness of both radiation and chemotherapy. A 2025 PubMed review confirmed that tumor hypoxia is a fundamental barrier to effective cancer therapy, driving resistance to radiotherapy, chemotherapy, and immunotherapy while fostering invasion and metastasis. [Source: PubMed 2025]

2. Mitochondrial Dysfunction

Cancer cells often reprogram their metabolism to rely on glycolysis (the Warburg effect) rather than oxidative phosphorylation. This metabolic shift produces less ATP and generates more reactive oxygen species (ROS), further damaging surrounding healthy tissue. Restoring mitochondrial function in normal cells creates a more hostile environment for this metabolic reprogramming. [March, 2016]

3. Chronic Inflammation

Persistent low-grade inflammation — reflected in elevated CRP, IL-6, and TNF-α — creates a pro-tumor microenvironment that suppresses immune surveillance and promotes tumor growth and spread. Reducing systemic inflammation is one of the most measurable outcomes of sustained HBOT.

4. Immune Dysregulation

Effective immune surveillance requires a balanced, active immune system with robust natural killer (NK) cell activity and T-cell function. Cancer — and many cancer treatments — suppress immune function. HBOT has been shown to enhance NK cell activity and modulate immune response, helping restore the body's intrinsic anti-tumor mechanisms. [Thom & Bhopale, StatPearls, 2023]

5. Oxidative Stress

Elevated oxidative stress markers — including 8-OHdG and malondialdehyde (MDA) — indicate DNA damage and impaired cellular repair. While HBOT does transiently increase reactive oxygen species (a key signaling mechanism), it simultaneously upregulates the body's antioxidant enzymes, including superoxide dismutase (SOD) and glutathione, ultimately reducing net oxidative damage over a course of treatment.

6. Impaired Detoxification

Cancer treatment — particularly chemotherapy — places an enormous burden on the liver, kidneys, and lymphatic system. When detoxification pathways are overwhelmed, treatment metabolites accumulate, toxicity rises, and recovery slows. Optimizing oxygenation and circulation directly supports detoxification organ function and lymphatic flow.

"Cancer does not simply appear. It establishes itself in a physiological environment that has become permissive to its survival. The terrain model changes the question from 'how do we destroy the tumor?' to 'how do we rebuild the environment that no longer tolerates it?'"

— Dr. Beth Meneley, DAOM, L.Ac., Founder, OxygenWell

How HBOT Restores the Terrain: The Physiological Mechanisms

HBOT does not address cancer directly. It addresses the six terrain dysfunctions listed above through measurable, well-documented physiological mechanisms that operate at the cellular level with every session:

Plasma Oxygen Increase: 10 to 15 Times Normal

Under pressure, oxygen dissolves into plasma in concentrations 10 to 15 times higher than breathing room air. This dissolved oxygen reaches ischemic, inflamed, and hypoxic tissue that hemoglobin-bound oxygen cannot access. For cancer patients, this means delivering oxygen to exactly the tissue environments that tumor cells have made hostile to normal cell function.

Inflammatory Cytokine Reduction

Peer-reviewed biomarker data shows consistent, measurable reductions in key inflammatory markers across a course of HBOT sessions:

BiomarkerBaselineAfter 20 SessionsAfter 40–60 Sessions CRP (mg/L)3.21.60.7 TNF-α (pg/mL)4.82.31.4 IL-6 (pg/mL)2.91.20.6 IL-1β (pg/mL)2.10.90.4 8-OHdG (ng/mL)6.33.21.7 SOD (U/mL)9801,4501,980 Glutathione (µM)6.28.912.6 CD34+ Stem Cells (per µL)1.54.26.8

Data from peer-reviewed studies including the Bryan Johnson longevity protocol biomarker series.

CD34+ Stem Cell Mobilization: Up to 8 Times Baseline

One of HBOT's most clinically significant effects in cancer support is the mobilization of CD34+ progenitor stem cells from bone marrow into circulation. After 10 sessions, CD34+ counts begin rising. After 40–60 sessions, concentrations reach up to 6.8 per µL — representing a mobilization rate up to 8 times baseline. These circulating stem cells drive tissue repair, angiogenesis, and immune reconstitution in patients whose bone marrow and tissue repair capacity has been depleted by chemotherapy or radiation.

Mitochondrial ATP Production

Increased plasma oxygen directly fuels mitochondrial oxidative phosphorylation, boosting ATP production in every cell. For cancer patients experiencing treatment-related fatigue — one of the most debilitating side effects of both chemotherapy and radiation — this restoration of cellular energy is clinically meaningful. A 2016 study confirmed that HBOT improves mitochondrial function and reduces oxidative stress in treated patients. [March, 2016]

NK Cell Activity Enhancement

Natural killer (NK) cells are among the immune system's most important anti-tumor defenses. HBOT enhances NK cell activity and may improve tumor oxygenation, making cancer cells more visible to immune surveillance and more vulnerable to immune-mediated destruction. [Thom & Bhopale, StatPearls, 2023]

Angiogenesis and Vascular Remodeling

HBOT stimulates vascular endothelial growth factor (VEGF) — triggering new capillary formation in oxygen-depleted tissue. This is particularly important for patients recovering from radiation therapy, where blood vessels are often permanently damaged, creating a cycle of ischemia and non-healing tissue. Restoring vascular supply to irradiated tissue is one of the FDA-approved indications for HBOT in cancer care.

Does HBOT Promote Cancer Growth? What the Evidence Says

This is the question every oncology patient and referring physician asks. The historical concern was that flooding the body with oxygen might "feed" tumor cells and accelerate growth. Current evidence does not support this concern.

The reality is more nuanced — and more favorable. Most tumors have already created their own hypoxic microenvironments specifically because hypoxia supports their survival strategy (glycolysis, angiogenesis, immune evasion). Reoxygenating the tissue environment disrupts this strategy. Research from a 2025 PubMed review on hyperbaric oxygen therapy in cancer treatment found that HBOT enhances drug penetration, augments radiation-induced DNA damage, alleviates hypoxia-driven immunosuppression, and synergizes with immune checkpoint blockade. [Source: PubMed 2025]

Additionally, a 2025 safety evaluation published in Medicina evaluated HBOT specifically for managing cancer treatment complications and confirmed its safety profile in this patient population. [Source: PMC 2025]

The key clinical principle: oxygenated tissues are generally more responsive to radiation therapy, not less. Tumor hypoxia is a well-established cause of radiation resistance. HBOT can help correct this.

As always, HBOT for cancer patients should be initiated only under qualified medical supervision, with full transparency to the patient's oncology team.

The 4-Phase HBOT Dose Model for Cancer Support

At OxygenWell, we use a structured, phase-based dosing model — DOSE • TIME • BIOLOGY = TRANSFORMATION — to guide treatment planning for cancer patients. Each phase produces distinct, measurable physiological changes:

Phase 1: Immediate Response (1 Session)

The first session delivers an immediate 10–15x increase in tissue oxygenation, a rapid boost in ATP production, and early reduction in edema and inflammation. Patients often notice reduced pain, improved mental clarity, and increased energy following initial sessions. Early neuroprotective signaling also begins in this phase.

Clinical impact: Pain reduction, cognitive clarity, energy restoration.

Phase 2: Threshold Phase (approximately 10 Sessions)

Around 10 sessions, the therapy crosses a critical threshold from symptomatic relief into regenerative medicine. VEGF rises, triggering capillary budding. CD34+ stem cells begin mobilizing from bone marrow — at up to 8 times baseline. Early neurogenesis begins. Inflammatory markers show sustained reduction.

Key transition: From symptom management to tissue-level repair and immune reconstitution.

Phase 3: Regenerative Acceleration (20–30 Sessions)

Mature angiogenesis establishes stable new vascular networks. Collagen synthesis accelerates, supporting tissue repair in irradiated or treatment-damaged areas. White matter repair and measurable improvements in cognitive function occur in this phase. Mitochondrial efficiency continues to improve.

Key outcomes: Tissue repair, wound healing, cognitive improvement, reduced chemo fog.

Phase 4: Longevity and Biomarker Shift (40–60 Sessions)

The most profound systemic changes occur in this phase. Telomere length increases (T/S ratio rising from 0.69 at baseline to 1.12 at 40–60 sessions). Senescent cell burden reduces by approximately 30–37%. Brain perfusion improves significantly. Sustained neurogenesis continues. Stem cells are released repeatedly, driving ongoing repair and cellular reconditioning.

Key outcomes: Cellular reprogramming for longevity, resilience, immune restoration, and sustained anti-aging effects — all highly relevant for cancer survivorship.

HBOT Timing Around Chemotherapy

Proper timing of HBOT sessions around chemotherapy cycles is critical. At OxygenWell, we follow a structured protocol designed to maximize support while avoiding contraindicated drug interactions:

Before Chemotherapy (Prehabilitation)

2 to 5 HBOT sessions per chemotherapy cycle, at 1.3–2.0 ATA, for 60–90 minutes per session. Pre-treatment sessions prime the body: tissues are better oxygenated, inflammatory burden is lower, and cellular energy reserves are higher. This positions the patient to tolerate chemotherapy with reduced toxicity.

After Chemotherapy (Recovery)

1 to 3 sessions within 24–72 hours following chemotherapy infusion, at 1.3–2.0 ATA, for 60–90 minutes. Post-treatment sessions support detoxification, reduce chemo-related inflammation, accelerate bone marrow recovery, and address the oxidative stress burden imposed by cytotoxic agents.

Between Cycles (Maintenance)

1 to 2 sessions per week between chemotherapy cycles, at 1.3–2.0 ATA, for 60–90 minutes. Maintenance sessions sustain the terrain improvements made in the pre- and post-treatment phases, preventing the progressive physiological decline that accumulates across multiple chemotherapy cycles.

Chemotherapy Drug Interactions and Contraindications

HBOT is safe and appropriate for the vast majority of cancer patients on chemotherapy. However, two classes of drugs carry absolute contraindications that require oncology clearance before any HBOT session:

Absolute Contraindications — Do Not Proceed Without Oncology Clearance

• Bleomycin: HBOT significantly increases the risk of severe pulmonary toxicity in patients who have received or are receiving bleomycin. This is an absolute contraindication. Oncology clearance is mandatory.
• Doxorubicin (Adriamycin): Concurrent HBOT increases the risk of cardiac toxicity and oxidative stress with this anthracycline. Oncology clearance is required.

Caution — Coordinate Timing with Oncology Team

• Cisplatin and Carboplatin: Risk of nephrotoxicity and ototoxicity. Monitor renal and auditory function closely. Timing and dosing coordination with the oncology team is essential.
• Methotrexate: Risk of tissue toxicity, mucositis, and delayed healing. HBOT should never be given the same day as methotrexate administration.
• Etoposide: Risk of myelosuppression and increased infection susceptibility. Blood count monitoring required.
• Cyclophosphamide: Risk of hemorrhagic cystitis and immune suppression. Bladder function monitoring and careful timing coordination required.

At OxygenWell, our clinical intake process includes a full medication review and direct coordination with your oncology team before beginning any cancer support protocol. Your safety is the foundation of everything we do.

HBOT and Radiation Therapy: Before, During, and After

The relationship between HBOT and radiation therapy spans three distinct phases of care, each with different clinical objectives:

Before Radiation

2 to 5 HBOT sessions per week, at 1.5–2.0 ATA, for 60–90 minutes. Pre-radiation sessions optimize tissue oxygenation, which directly enhances radiation effectiveness. Well-oxygenated cells generate more free radicals in response to ionizing radiation, amplifying radiation-induced DNA damage to tumor cells.

During Radiation

2 to 5 sessions per week as tolerated, at 1.5 ATA, for 60–90 minutes. Sessions during active radiation treatment focus on protecting healthy surrounding tissue and reducing treatment-related inflammation and fatigue.

After Radiation: Treating Radiation-Induced Injury

HBOT is an FDA-approved, insurance-covered treatment for delayed radiation injuries — one of the strongest evidence bases for HBOT in oncology. Conditions treated include:

• Osteoradionecrosis (ORN): Bone necrosis in irradiated areas, including the mandible (Marx Protocol: 20 pre-operative sessions at 2.0–2.5 ATA, followed by 10 post-operative sessions — shown to reduce ORN incidence from 29.9% to 5.4% in published data. [Marx RE et al., 1985])
• Soft Tissue Radionecrosis (STNR): Non-healing tissue damage in previously irradiated fields.
• Radiation Cystitis: Bladder injury following pelvic radiation.
• Radiation Proctitis: Rectal injury following pelvic or colorectal radiation.

Protocol for radiation injury treatment: 20–40+ sessions at 2.0–2.4 ATA, 90 minutes per session, five times per week. Medicare and PPO insurance cover these indications when medical necessity criteria are met.

A 2024 study published in JAMA Oncology (the Dutch HONEY trial) found that breast cancer patients who completed HBOT for late radiation toxicity experienced measurable reductions in pain and fibrosis. [Source: ASCO Post, 2024]

Combined HBOT and Photobiomodulation (PBM) Protocol

OxygenWell offers a combined HBOT and Photobiomodulation (PBM) protocol specifically designed for cancer patients. PBM — also known as red light therapy — uses specific wavelengths of light to stimulate mitochondrial activity, reduce inflammation, and accelerate tissue repair at both superficial and deep tissue levels.

PBM Wavelengths Used at OxygenWell

• Red light (630–660 nm): Superficial healing, lymphatic drainage, local inflammation reduction.
• Near-infrared (810–880 nm): Deeper mitochondrial and systemic recovery, neural tissue support.

Timing During Chemotherapy

PBM is generally safe during chemotherapy when used appropriately, with one important precaution: direct application over active tumor sites should be avoided. Recommended timing follows the same structure as HBOT:

• After chemotherapy: ideally 24–72 hours post-infusion.
• Between cycles: maintenance sessions for ongoing mitochondrial support.
• Same day (if needed): shorter, lower-intensity sessions.

The combination of HBOT and PBM creates a synergistic effect: HBOT floods tissue with dissolved oxygen while PBM stimulates the mitochondria to use that oxygen more efficiently. For cancer patients managing treatment fatigue, neuropathy, and tissue injury, this combination protocol represents a meaningful advance in supportive care.

What the Research Shows: Key Clinical Citations

OxygenWell's oncology protocols are grounded in published, peer-reviewed literature. Key references supporting our approach include:

• Quality of life and fatigue reduction: A meta-analysis published in Supportive Care in Cancer (2016) found that HBOT significantly improves quality of life and reduces fatigue in cancer patients — two of the outcomes patients and caregivers consistently prioritize. [Support Care Cancer, 2016]
• Immune function and tumor oxygenation: Thom and Bhopale, writing in StatPearls (2023), documented HBOT's capacity to enhance immune function and potentially improve tumor oxygenation — making tumors more responsive to conventional treatment. [StatPearls, 2023]
• Mitochondrial function and oxidative stress: Published data (March, 2016) confirmed HBOT's ability to improve mitochondrial function and reduce oxidative stress in treated patients — directly addressing two core terrain dysfunctions in cancer care.
• Radiation injury treatment: UCLA Health and multiple peer-reviewed sources confirm HBOT as an effective, established treatment for long-term radiation-induced tissue damage. [UCLA Health]
• Breaking the hypoxia barrier: A 2025 PubMed review confirmed HBOT's emerging role in tumor reoxygenation, immune checkpoint synergy, and enhancement of drug penetration — among the most clinically significant findings in integrative oncology in recent years. [PubMed, 2025]

Long-Term Survivorship Support

Cancer survivorship presents its own distinct physiological challenges. Patients who have completed active treatment often carry the long-term burden of treatment-related damage: cognitive impairment (chemo fog), peripheral neuropathy, persistent fatigue, hormonal disruption, impaired immune function, and psychological strain. These are not simply residual side effects — they reflect ongoing cellular dysfunction that, without intervention, tends to persist or worsen.

HBOT's Phase 4 biomarker effects are particularly relevant to survivorship. At 40–60 sessions, the data shows:

• Telomere lengthening (T/S ratio: 0.69 at baseline → 1.12 at 40–60 sessions)
• 30–37% reduction in senescent cell burden
• Significant improvement in brain perfusion and cognitive function
• Sustained stem cell mobilization driving ongoing tissue repair
• Normalization of inflammatory markers to near-optimal ranges

For cancer survivors, these are not merely "wellness" outcomes. They represent the cellular infrastructure of long-term health — the difference between surviving cancer and rebuilding a life that thrives after it.

OxygenWell also offers complementary services that support comprehensive survivorship care:

• Bioidentical Hormone Therapy (BHRT): Many cancer survivors — particularly post-menopausal women and men treated with hormonal therapies — require careful hormone optimization to restore energy, bone density, and quality of life.
• Functional Medicine: Root-cause analysis addressing gut health, detoxification pathways, mitochondrial function, and immune system reconstitution using the 5R model.
• Targeted supplement protocols: Including glutathione (liposomal), CoQ10 Ubiquinol, Vitamin C, NAC, medicinal mushrooms, and adaptogens — all selected to support the terrain repair process and complement HBOT outcomes.

OxygenWell's membership programs provide a practical framework for survivors seeking consistent, long-term cellular support in a medically guided environment.

Why OxygenWell for Integrative Oncology Support

Not all hyperbaric oxygen facilities are the same. California law requires hyperbaric facilities to be physician-owned — and OxygenWell was founded and is directed by Dr. Beth Meneley, DAOM, L.Ac., a physician with 25+ years in integrative medicine and 12+ years dedicated specifically to hyperbaric medicine. Most centers operate without this level of clinical oversight.

What Sets OxygenWell Apart

• Physician-owned and physician-directed: California law mandates physician ownership of hyperbaric facilities. OxygenWell was built to this standard from the ground up.
• FDA-cleared chambers rated to 2.4 ATA: Full-rated pressure — not "adjusted" to 2.0 ATA as many centers are forced to operate. Actual pressure matters for clinical outcomes.
• Medical-grade oxygen delivery system: A high-flow system, not a standard 10-liter oxygen concentrator. The quality of oxygen delivery directly affects treatment efficacy.
• Insurance accepted: Medicare and PPO insurance accepted for all FDA-approved indications, including radiation injury treatment. Our billing team handles all pre-authorizations.
• Grounded, monoplace chambers: Electrical grounding reduces fire risk and meets the highest available safety standards.
• On-site safety leadership: A Safety Director with 12+ years of hyperbaric experience. Certified Hyperbaric Technicians (CHTs), most of whom are EMT-certified. A Physician Assistant on-site during most weekday hours.
• 50,000+ supervised HBOT sessions: Experience matters in hyperbaric medicine. No other comparable facility in Los Angeles approaches this level of clinical experience.
• Extended hours including evenings and weekends: Monday through Friday 9 AM to 9 PM; Saturday and Sunday 10 AM to 6 PM. Rare among HBOT centers and designed for working patients and those managing treatment schedules.
• Two convenient Los Angeles locations: Sherman Oaks (inside Sherman Oaks Galleria) and Calabasas.

Our commitment is simply stated: Advanced Technology. Grounded Chambers. Medical Grade Oxygen. Proven Safety.

Ready to Discuss Your Cancer Support Protocol?

If you or a loved one are navigating a cancer diagnosis, treatment, or recovery, we invite you to speak directly with our clinical team. We will review your treatment history, current medications, and oncology team's plan — and design an HBOT protocol that supports your healing safely and effectively.

Call us: (818) 661-0939
Locations: Sherman Oaks | Calabasas
Hours: Monday–Friday 9 AM–9 PM | Saturday–Sunday 10 AM–6 PM
Insurance: Medicare and PPO accepted for FDA-approved indications
Website: www.oxygenwell.com

HEAL DEEPER. RECOVER FASTER. PERFORM BETTER. LIVE LONGER.

About the Author

Dr. Beth Meneley, DAOM, L.Ac. is the Founder and Wellness Director of OxygenWell Hyperbaric & Regenerative Medicine Center, with locations in Sherman Oaks and Calabasas, California. She brings over 25 years in integrative medicine and 12+ years dedicated to hyperbaric medicine in Los Angeles, having directly supervised more than 50,000 HBOT sessions.

Dr. Meneley holds a Doctorate in Acupuncture and Oriental Medicine (DAOM) and is a certified Functional Medicine practitioner with specialized expertise in integrative oncology, bioidentical hormone therapy, and epigenetics. Her approach to patient care is grounded in the terrain model and root-cause medicine — identifying and correcting the physiological dysfunction that underlies disease, rather than managing symptoms in isolation.

Her personal history informs her deep commitment to cancer care: Dr. Meneley lost her father and both brothers to cancer. This profound experience fuels her dedication to integrative healing and was a catalyst in founding OxygenWell as a center where patients receive not only medical excellence, but genuine compassion.

This article is for educational purposes only and does not constitute medical advice. Always consult your oncology team before beginning any complementary therapy.